Treatment of Breast Cancer
common.study.values.description
“Copper (Cu) 64-DOTA-Trastuzumab PET Imaging in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Patients With HER2 Positive Breast Cancer”
This phase II trial studies how well copper Cu64-DOTA-trastuzumab positron emission tomography (PET) works in predicting response to treatment with trastuzumab and pertuzumab before surgery in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer that has spread from where it started to nearby tissue or lymph nodes. Diagnostic procedures, such as copper Cu 64 DOTA-trastuzumab PET, may help predict a patient's response to trastuzumab and pertuzumab before surgery in patients with locally advanced HER2 positive breast cancer.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-no
common.study.methods.is-healthy-no
Radiation - Copper Cu 64-DOTA-Trastuzumab
Given IV
Laboratory Biomarker Analysis
Correlative studies
Biological - Pertuzumab
Given IV
Procedure - Positron Emission Tomography
Undergo PET
Procedure - Therapeutic Conventional Surgery
Undergo surgery
Biological - Trastuzumab
Given IV
participant.views.study.view.additional
participant.views.study.view.scientific-title
Use of 64Cu-DOTA-Trastuzumab PET Imaging and Molecular Markers for Prediction of Response to Trastuzumab and Pertuzumab-Based Neoadjuvant Therapy
common.study.values.clinical-trial-id
NCT02827877
participant.views.study.view.id
ZdPGAb
